CRISPR Therapeutics COO Lawrence Klein resigns; search for successor underway

CRISPR Therapeutics AG

COO Lawrence Klein, Ph.D., resigns effective Oct 27, 2022; will stay through year-end for transition.
CEO Samarth Kulkarni thanked Klein for seven years of contributions to strategy and leadership.
Company is conducting a search to find a successor for the COO role.
Klein cited exa-cel poised for regulatory filing and five other clinical programs as company strengths.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Lawrence O. Klein

Chief Operating Officer

CRSP · CRISPR Therapeutics AG

Effective: 2022-10-27
Filed: October 27, 2022, 7:59 PM ET

On October 27, 2022, Lawrence O. Klein, Ph.D. resigned from his position as Chief Operating Officer of CRISPR Therapeutics AG.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lawrence O. Klein resigned as Chief Operating Officer at CRISPR Therapeutics AG.

Action: resigned
Role: Chief Operating Officer

Exact text from the filing

On October 27, 2022, Lawrence O. Klein, Ph.D. resigned from his position as Chief Operating Officer of CRISPR Therapeutics AG.

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-22-020257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.